Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236876 | 0.90 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL4244227 | 0.89 | CCR5 (0.51) | CCR5 | |
| SCHEMBL4236635 | 0.88 | CCR5 (0.50) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL4238957 | 0.84 | CCR5 (0.49) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL13931519 | 0.83 | CCR5 (0.66) | CCR5KCNH2 | |
| SCHEMBL4242973 | 0.82 | CCR5 (0.53) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL4586211 | 0.81 | CCR5 (0.43) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL4240580 | 0.81 | CCR5 (0.44) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL4242938 | 0.81 | CCR5 (0.41) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL4248486 | 0.81 | CCR5 (0.44) | CCR5KCNH2UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | claimed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | claimed |
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CCR5 1/4885SIGMAR1 890/4885KCNH2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.